Pancreatic ductal adenocarcinoma is a devastating disease, and patient outcomes have not
improved in decades. Treatments that target tumor cells have largely failed. This could be …

Tumour-stromal interactions have now been acknowledged to play a major role in
pancreatic cancer (PC) progression. The abundant collagenous stroma is produced by a …

Background The prognosis of pancreatic cancer remains desperately poor, with little
progress made over the past 30 years despite the development of new combination …

Background Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant disease with a
very poor prognosis. To date patient outcomes have not improved principally due to the …

Pancreatic cancer—a tumor displaying a particularly abundant stromal reaction—is
notorious for its poor prognosis. Recent studies, via newly developed orthotopic models …

Pancreatic stellate cells (PSCs) are responsible for producing the collagenous stroma in
pancreatic cancer. Findings from the majority of in vitro and in vivo studies to date indicate …

Pancreatic cancer is characterised by a prominent desmoplastic/stromal reaction that has
received little attention until recent times. Given that treatments focusing on pancreatic …

Pancreatic stellate cells (PSCs) were identified in the early 1980s, but received much
attention after 1998 when the methods to isolate and culture them from murine and human …

One of the characteristic features of the majority of pancreatic ductal adenocarcinomas is an
abundant desmoplastic/stromal reaction. Until recently, this stroma had received little …

Pancreatic ductal adenocarcinoma (PDAC) is a gastrointestinal malignancy with a dismal
clinical outcome. Accumulating evidence suggests that activated pancreatic stellate cells …